English translation

Summary of Financial Results
for the Second Quarter of Fiscal Year Ending December 31, 2013
[Japanese GAAP] (Non-Consolidated)
August 7, 2013
Company Name

SymBio Pharmaceuticals Limited

Listing: Tokyo Securities Exchange

Securities Code4582

URL http://www.symbiopharma.com/

Representative

Representative Director, President andChief Executive Officer

Fuminori Yoshida

Contact Person

Executive Vice President, CFO andHead of Corporate Div.

Takashi Shimomura

TEL 03(5472)1125

Scheduled Date to File
Quarterly ReportAugust 8, 2013

Date of Dividend
Payment (plan)－

Supplementary Materials for the
Quarterly Financial Results:

Yes

No

Holding of Quarterly Earnings
Performance review:Yes

No (for securities analysts and institutional investors)(Millions of yen – rounded down, unless otherwise stated）
1. Business Results for the Second Quarter of FY 2013 (January 1, 2013 to June 30, 2013)(1) Operating Results (cumulative)(percentages indicate year-on-year changes)
Quarterly Net Income
Net Sales
Operating Income (loss) Ordinary Income (loss)(loss)
millions of yen%

millions of yen%

millions of yen%

millions of yen

%

810
1,054

(23.1)
7.3

(807)
(874)

－
－

(812)
(895)

－
－

(814)
(897)

－
－

2Q FY 2013
2Q FY 2012

Quarterly Net Income(loss) per share

Diluted Net Income per
share

Yen
Yen
2Q FY 2013(36.65)－2Q FY 2012(46.92)－(Note) Despite the issuance of stock acquisition rights, information in connection with diluted quarterly net profit per share notdisclosed due to quarterly net loss per share.
(2) Financial position
Total Assets
2Q FY 2013 (As of June 30, 2013)
FY 2012 (As of December 31, 2012)

millions of yen
5,986
5,502

Net Assets

Equity Ratio

millions of yen
5,375
4,899

Net Assets per Share
%
88.8
88.6

(Reference) Net assets excluding subscription rights to shares:
2Q FY 2013 (As of June 30, 2013)

5,316 million yen

FY 2012 (As of December 31, 2012)

4,872 million yen

Yen
230.65254.71

2. Dividends

FY 2012FY 2013
FY 2013 (Forecast)

1st Quarter
Yen－－

Annual Dividend per Share
2nd Quarter
3rd Quarter
Fiscal Year End
Yen
Yen
Yen
0.00
－
0.00
0.00
－
0.00

(Note) Revisions to the dividends forecast recently announced:

Yes ・ No

Full Year
Yen
0.00
0.00

English translation

3. Earnings Forecast for FY 2013 (January 1, 2013 to December 31, 2013)
Operating
Income (loss)

Net Sales

Full Year

Ordinary
Income (loss)(percentages indicate year-on-year changes)
Net Income (loss)
Net Income (loss)
per share

Millions ofyen%Millions ofyen%Millions ofyen%Millions of
yen

%

Yen

1,563

(20.1)(1,743)－(1,749)－(1,753)－(76.10)Yes ・ No

(Note) Revision to the earnings forecasts most recently announced:

Notes:(1) Application of special accounting treatment in
preparation of quarterly financial reports:

Yes ・ No

(2) Changes in accounting policies, accounting estimates and restatements after error corrections(a) Changes in accounting polices due to revisionof accounting standards:

Yes ・ No(b) Changes in accounting polices due to otherreason(s):Yes(c) Changes in accounting estimates:

Yes ・ No(d) Restatement after error corrections:

Yes ・ NoNo(3) Number of shares outstanding (common stock)(i) Number of shares outstanding at the end of

2Q FY 2013

23,052,157 shares

FY 2012

19,130,900 shares(ii) Number of shares of treasury stock at endof the period

2Q FY 201375 shares

FY 201275 shares(iii) Average number of shares during the period(cumulative)

2Q FY 2013

22,212,523 sharesperiod (including treasury stock)

2Q FY 2012

19,130,825 shares* The status of quarterly review
The review of quarterly financial statements as required by the Financial Instruments and Exchange Act is proceeding as of thedate of this disclosure document.
* Explanation regarding the appropriate use of earnings forecasts and other matters
All forecasts presented in this document including earnings forecasts are based on the information currently available tomanagement and assumptions judged by management to be reasonable. Actual results may differ substantially from these
forecasts contained herein due to various factors. Regarding the assumptions on which the earnings forecasts are based and theiruse usage, please refer to “1. Qualitative Information Concerning Quarterly Financial Results, (3) Qualitative information
concerning earnings forecasts” on Page 2 of the following attachment.

SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Second Quarter of Fiscal Year Ending December 31, 2013

Index of Attachment
1. Qualitative Information Concerning Quarterly Financial Results ……………………………………………………

1(1) Qualitative information concerning business results ………………………………………………………………

1(2) Qualitative information concerning financial position …………………………………………….………………

2(3) Qualitative information concerning earnings forecasts …………………………………………………….………

2

2. Quarterly Financial Statements …………………………………………………………………………………..……

3(1) Balance sheets ……………………………………………………………………………………………………..

3(2) Statements of operations……………………………………………………………………………………………

5

Statements of operations (cumulative) …………………………………………………………………………

5(3) Quarterly cash flow statement……………...………………………………………………………………………

6(4) Notes concerning going concern assumption………………………………………………………………………

8(5) Notes concerning significant changes in shareholders’ equity ………………………………….…………………

8

SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Second Quarter of Fiscal Year Ending December 31, 2013

1. Qualitative Information Concerning Quarterly Financial Results(1) Qualitative information concerning business results
Progress in the Company’s business for the second quarter of FY 2013 is as follows:(i) Domestic[SyB L-0501 (generic name: bendamustine hydrochloride, trade name: TREAKISYM®)]
The Company sells an anticancer drug (SyB L-0501) in Japan through its business partner, Eisai Co., Ltd. (Eisai), for theindications of refractory/relapsed indolent non-Hodgkin’s lymphoma (NHL) and mantle cell lymphoma (MCL).
The Company continues to conduct clinical trials for TREAKISYM® in additional indications.
Regarding Phase II clinical trial (collaborative trial in Japan and South Korea) for refractory/relapsed aggressive NHL,
despite the completion of analysis and evaluation of the clinical trial data, the Company temporarily suspended theapplication for approval of the indication planned to be submitted in the previous fiscal year, based on the results of a preapplication meeting with the Pharmaceuticals and Medical Devices Agency (PMDA), and continuing discussions with theagency.
For the frontline Low-grade NHL and MCL indications, Phase II patient enrollment was completed in March 2013 with
the Phase II trial for refractory/relapsed multiple myeloma underway.
Clinical trial notification to conduct a Japanese Phase II trial for chronic lymphocytic leukemia was accepted in
December 2012, with the first patient enrolled in May, 2013. TREAKISYM® was also designated as an orphan drug for theindication of chronic lymphocytic leukemia in June, 2012.
In addition, the Company received a notice of release from the special drug use results survey in March 2013, an
extensive survey, which was a pre-condition for approval of the refractory/relapsed indolent NHL and MCL indications, by
the Ministry of Health, Labour and Welfare.
[SyB L-1101 (intravenous form)/C-1101 (oral form) (generic name: rigosertib)]
Regarding the IV form of rigosertib (SyB L-1101), an anticancer drug indicated, for refractory/relapsed high-risk
myelodysplastic syndrome (MDS), the first patient has been enrolled in the Japanese Phase I clinical trial.
As for the oral form of rigosertib (SyB C-1101) indicated for low-risk MDS, patient enrollment for the Japanese Phase I
trial was initiated in March 2013.
[SyB D-0701]
In January 2013, we completed our Phase II clinical trial for SyB D-0701 (a transdermal antiemetic patch) for theindication of radiotherapy-induced nausea and vomiting. The future direction of development is now under consideration.
(ii) Overseas
Sales of SyB L-0501 are going well. The drug is being marketed in Taiwan through the Taiwanese company
InnoPharmax Inc. and in Singapore and South Korea through local subsidiaries of Eisai (local subsidiaries).
(iii) Fund procurement
The Company passed a resolution on December 27, 2012 to issue the first unsecured convertible bond with stockacquisition rights (total issue price: 1 billion yen) with Whiz Healthcare PE Series 1 Investment Limited Liability
Partnership as the allottee and the 29th warrant (total issue price: 5.1 million yen, total issue price of stocks when issued
through the exercise of the stock acquisition rights: 500 million yen), with the aim of accelerating the development of new
drug candidates and further reinforcing the pipeline. Accordingly, Whiz Healthcare PE Series 1 Investment Limited
Liability Partnership completed payment of 1,005,100 thousand yen to the Company on January 15, 2013.
In January 2013, the 29th series stock option was partially exercised and the total paid-in amount of 199,998 thousand
yen has been received.
(iv) Business results
As a result of the aforementioned developments, net sales totaled 810,807 thousand yen (a year-on-year decrease of
23.1 %) following review of the current market inventory level, for the second quarter of the fiscal year ending December
31, 2013, primarily reflecting sales of SyB L-0501 in Japan and Asian countries.
Selling, general and administrative expenses totaled 991,517 thousand yen (a year-on-year decrease of 13.0%), including
research and development (“R&D”) expenses of 556,536 thousand yen (a year-on-year decrease of 20.3 %) for the accrualof expenses associated with the clinical trials for multiple indications of SyB L-0501 and clinical trials and preparations for-1-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Second Quarter of Fiscal Year Ending December 31, 2013

SyB L-1101 as well as other selling, general and administrative expenses of 434,981 thousand yen (a year-on-year decreaseof 1.4 %).
As a result, we posted an operating loss of 807,162 thousand yen for the first six months ended June 30, 2013 (operating
loss of 874,322 thousand yen for the same period in the previous fiscal year). In addition, the Company recorded a total of
10,264 thousand yen as non-operating expenses, primarily comprising commission fees and stock issuance costs, and otherfactors which led to an ordinary loss of 812,231 thousand yen (ordinary loss of 895,748 thousand yen for the same period in
the previous fiscal year) and net loss of 814,131 thousand yen (net loss of 897,688 thousand yen for the same period in theprevious fiscal year).
Segment information has been omitted in the summary of business results given that the Company operates a single
segment of the pharmaceutical business including research and development of pharmaceutical drugs as well as
manufacturing, marketing and other related activities.

(2) Qualitative information concerning financial positions
Total assets as of June 30, 2013 stood at 5,986,895 thousand yen, an increase of 484,704 thousand yen from the previous
fiscal year end. Total current assets increased by 501,718 thousand yen from the previous fiscal year end to 5,922,342
thousand yen, primary due to both marketable securities increased by 1,223,305 thousand yen and cash and deposits
decreased by 893,292 thousand yen arising from fund procurement and increased inventories by 217,433 thousand yen
following review of safety stock levels of TREAKISYM®. Total noncurrent assets stood at 64,552 thousand yen a decreaseof 17,014 thousand yen primary due to decrease of long-term prepaid expenses by 11,829 thousand yen from the previous
fiscal year end.
Total liabilities stood at 611,764 thousand yen, the same level from the previous year end (total liability of 602,232
thousand yen as of the previous fiscal year end).
Net assets increased by 475,175 thousand yen from the previous fiscal year end to 5,375,130 thousand yen due to anincrease in capital stock and capital surplus by 621,819 thousand yen respectively arising from fund procurement despite ina net loss of 814,131 thousand yen. As a result, the equity ratio increased by 0.2 percentage points to 88.8% from theprevious fiscal year end.

(3) Qualitative information concerning earnings forecasts
No revision has been made to the earnings forecast for FY 2013 as of the date of this document.

-2-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Second Quarter of Fiscal Year Ending December 31, 2013

2. Quarterly Financial Statements(1) Balance sheets(nit: Thousand yen)
FY 20122Q FY 2013(as of December 31, 2012)(as of June 30, 2013)

AssetsCurrent assets
Cash and deposits
Accounts receivable-trade

4,540,022
148,0813,646,729
168,045

Marketable securities
Merchandise and finished goods

300,000
164,571

1,523,305
382,005

Prepaid expenses
Advances paid

98,192
99,036

61,708110,376

Other
Total current assets

70,71830,1695,420,623

5,922,342

2,637

2,541

Noncurrent assets
Property, plant and equipment
Buildings, net
Tools, furniture and fixtures, net

11,084

8,635

Total property, plant and equipment

13,721

11,177

SoftwareLease assets

8,324
2,540

7,111
2,216

Total intangible assets

10,864

9,327

Investments and other assets
Long-term prepaid expenses

27,646

15,816

Lease and guarantee deposits

29,33428,231

Total investments and other assets

56,98044,048Intangible assets

Total noncurrent assets

81,56764,5525,502,190

5,986,895

Accounts payable-trade
Accounts payable-other329,768
195,833

370,752
173,421

Income taxes payable
Other

15,58857,33615,92848,427

Total current liabilities

598,527

608,528

1,688

1,559

Other

2,017

1,677

Total noncurrent liabilities

3,705

3,236

602,232

611,764

Total assets
Liabilities
Current liabilities

Noncurrent liabilities
Provision for retirement benefits

Total liabilities-3-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Second Quarter of Fiscal Year Ending December 31, 2013

(Unit: Thousand yen)
FY 20122Q FY 2013(as of December 31, 2012)(as of June 30, 2013)

Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Valuation and translation adjustments
Valuation difference on available-for-salesecurities
Total valuation and translation adjustments
Subscription rights to shares
Total net assets
Total liabilities and net assets

6,024,610
5,994,610

6,646,429
6,616,429(7,146,411)(17)(7,960,542)(17)－

14,666－

14,666

4,872,790-4-5,302,298

27,167

58,165

4,899,957

5,375,130

5,502,190

5,986,895

SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Second Quarter of Fiscal Year Ending December 31, 2013

(2) Statements of operations (cumulative)(for the second quarter of fiscal year ending December 31, 2013)(Unit: Thousand yen)
2Q FY 2012

2Q FY 2013

(from January 1, 2012
to June 30, 2012)(from January 1, 2013
to June 30, 2013)

Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating loss
Non-operating income
Interest income
Interest on securities
Interest on tax refunded
Foreign exchange gain
Other
Total non-operating income
Non-operating expenses
Interest expenses
Commission fee
Stock issuance cost
Foreign exchange losses
Other
Total non-operating expenses
Ordinary loss
Extraordinary loss
Loss on disposal of fixed assets
Total extraordinary loss
Loss before income taxes
Income taxes-current
Total income taxes
Net loss

1,054,302

810,807788,804

626,452

265,497

184,354

1,139,819

991,517(874,322)(807,162)

1,475
654

1,351
104

－
－

779
172

2,908

5,195

778

118

16

5,385
－

5,355
4,791

18,510320－
100

24,334

10,264(895,748)(812,231)

39

－

39

(895,788)
1,900

-5-

2,786

－

(812,231)
1,900

1,900

1,900

(897,688)(814,131)

SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Second Quarter of Fiscal Year Ending December 31, 2013

(3) Quarterly cash flow statement(Unit: Thousand yen)First six months of Fiscal 2012
(from January 1, 2012

First six months of Fiscal 2013
(from January 1, 2013

to June 30, 2012)

to June 30, 2013)

Cash flow from operating activities
Quarterly (loss) before tax(895,788)(812,231)

Depreciation
Amortization of security deposit

4,178
626

4,081
732

39

－

Loss on disposal of fixed assets
Increase (decrease) in allowance for retirement
benefits
Share-based compensation expense

(167)

(129)

7,327

27,938Interest income
Interest expense(2,253)
118(4,138)16

Foreign exchange loss (gain)
New share issuing expense

2,280
－

(10,528)
4,791

Commission paid
Decrease (increase) in accounts receivable

5,385(144,880)

5,355(19,964)

Decrease (increase) in inventories
Decrease (increase) in prepaid expenses

96,261(44,581)(217,433)
31,128Decrease (increase) in advances
Decrease (increase) in consumption tax receivable(24,235)－(11,340)
15,401

Decrease (increase) in other current assets
Decrease (increase) in long-term prepaid expenses

74,666(11,381)

25,293
11,829

Increase (decrease) in trade accounts payable
Increase (decrease) in other accounts payable

16,398(58,256)

40,983(22,429)

Increase (decrease) in other current liabilities
Increase (decrease) in other long-term liabilities

28,276(335)(17,563)
(340)

Other

147

100

(946,173)(948,444)

Interest and dividends received
Interest paid

2,196
(96)

3,551
－

Income taxes paid

(1,900)(1,900)(945,974)(946,792)－－(488,860)
300,000

Payment for purchase of marketable securities
Proceeds from redemption of marketable securities(300,000)
100,000(1,499,205)
300,000

Expenditures for purchase of intangible fixed assets
Payment for fixed leasehold deposit and security

(630)

－

(7,995)－－370(208,625)(1,387,695)

Subtotal

Cash flow from operating activities

(

(

(

Cash flow from investing activities
Transfer to time-deposits
Transfer from time-deposits

deposit
Proceeds from redemption of fixed leasehold deposit
and security deposit
Cash flow from investing activities

-6-

(
(

SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Second Quarter of Fiscal Year Ending December 31, 2013

(Unit: Thousand yen)First six months of Fiscal 2012
(from January 1, 2012

First six months of Fiscal 2013
(from January 1, 2013

to June 30, 2012)

to June 30, 2013)

Cash flow from financing activities
Proceeds from issuance of new stock on executing ofstock acquisition right－

241,598

Proceeds from issuance of new convertible bond withstock acquisition right－

1,000,000

Proceed from stock acquisition right
Payment for issuance of new stock

－
－

5,100
(4,791)Other expenditures

－

(100)

Cash flow from financing activities－

1,241,806(1,758)2,208

Increase (decrease) in cash and cash equivalents(1,156,358)(1,090,472)

Cash and cash equivalents at the beginning of the period

6,310,9784,240,022

Cash and cash equivalents at the end of the period

5,154,619

3,149,549

Effect of foreign exchange rate changes on cash and cash
equivalents-7-

SymBio Pharmaceuticals Limited (4582) Summary of Financial Results [Japanese GAAP] (Non-consolidated)
Results for the Second Quarter of Fiscal Year Ending December 31, 2013

(4) Notes concerning going concern assumption
None(5) Notes concerning significant changes in shareholders’ equity
Based upon the resolution at the Company’s Board of Directors meeting held on December 27, 2012, the Company issued
the 1st unsecured convertible bond with stock acquisition rights and the 29th series stock option on January 15, 2013 andreceived the proceeds in the amount of 1,005,100 thousand yen on the same date.
With regard to the 1st unsecured convertible bond with stock acquisition rights, all rights with face value of 1,000,000
thousand yen have been exercised by February 27, 2013. As for the 29th series stock option, 20 units (26,525 shares per unit)
were exercised on January 25, 2013 and the proceeds of 199,998 thousand yen received.
As a result of these primary events, capital stock and capital surplus increased by 621,819 thousand yen to 6,646,429
thousand yen and 6,616,429 thousand yen, respectively, as of June 30, 2013.

-8-